Showing 2611-2620 of 5909 results for "".
- NUST MISIS Scientists Say They Developed a Safe Drug to Treat Eye Inflammationhttps://modernod.com/news/nust-misis-scientists-say-they-developed-a-safe-drug-to-treat-eye-inflammation/2479203/A Russian-American research team from The National University of Science and Technology MISIS has presented a new therapeutic method using nanoparticles of an antioxidant enzyme, developed specifically for the eyes. It relieves inflammation and repairs tissue without causing side effects: irritat
- Lumenis Named “Best Overall Medical Device Company” in 2021 MedTech Breakthrough Awardshttps://modernod.com/news/lumenis-named-best-overall-medical-device-company-in-2021-medtech-breakthrough-awards/2479201/Lumenis announced that it has been selected as the “Best Overall Medical Device Company” in the MedTech Breakthrough Awards. MedTech Breakthrough is an independent market intelligence organization that honors excellence and recognizes the top companies, technologies and products in the global he
- Euclid Systems Launches New Euclid MAX Ortho-K Lenshttps://modernod.com/news/euclid-systems-launches-new-euclid-max-ortho-k-lens/2479200/Euclid Systems announced the United States launch of the overnight orthokeratology lens Euclid MAX. Used in children and adult patients with progressive myopia, but especially children, Ortho-K contact lenses gently reshape the cornea to manage myopia while the patient sleeps. “Euclid MAX
- Johnson & Johnson Vision Announces FDA Approval of Acuvue Abiliti Overnight Therapeutic Lenses for Myopia Managementhttps://modernod.com/news/johnson-johnson-vision-announces-fda-approval-of-acuvue-abiliti-overnight-therapeutic-lenses-for-myopia-management/2479199/Johnson & Johnson Vision Care announced that the FDA has approved Acuvue Abiliti-Overnight Therapeutic Lenses. This is the first and only FDA approved orthokeratology (ortho-k) contact lens for the management of myopia. “The FDA approval of Abiliti Overnight marks an
- Mount Sinai Ophthalmologists Develop New Technique to Assess Progression of Sickle Cell Retinopathyhttps://modernod.com/news/mount-sinai-ophthalmologists-develop-new-technique-to-assess-progression-of-sickle-cell-retinopathy/2479189/Ophthalmologists at New York Eye and Ear Infirmary of Mount Sinai have created a new technique to evaluate patients with sickle cell retinopathy and assess the disease before it progresses and leads to permanent vision loss. Using optical coherence tomography (OCT) angiography, the resear
- Tarsus Pharmaceuticals Initiates Saturn-2 Phase 3 Trial Evaluating the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitishttps://modernod.com/news/tarsus-pharmaceuticals-initiates-saturn-2-phase-3-trial-evaluating-the-safety-and-efficacy-of-tp-03-for-the-treatment-of-demodex-blepharitis/2479179/Tarsus Pharmaceuticals announced that it has commenced enrollment in Saturn-2, its second pivotal trial evaluating the company’s novel investigational treatment, TP-03, in patients with Demodex blepharitis. Up to 25 million Americans may be affected by Demodex blepharitis, which is caused by an i
- Verana Health: Study Demonstrates Promise of Real-World Data in Ophthalmic Clinical Developmenthttps://modernod.com/news/verana-health-study-demonstrates-promise-of-real-world-data-in-ophthalmic-clinical-development/2479172/Verana Health unveiled research during the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. In a first-of-its kind study, Verana Health demonstrated that it was able to successfully use
- CooperVision Expands Prescription Options for Biofinity XR Toric Contact Lenseshttps://modernod.com/news/coopervision-expands-prescription-options-for-biofinity-xr-toric-contact-lenses/2479170/CooperVision is introducing a broader range of expanded parameters for its Biofinity XR toric lenses. The addition of sphere powers from ±10.50D to ±20.00D nearly doubles the number of available prescription options specific to this lens, making it easier for eye care professionals to fit patient
- Novartis’ Sandoz Unit Confirms Late-Stage Clinical Development Plans for Proposed Biosimilar Aflibercepthttps://modernod.com/news/novartis-sandoz-unit-confirms-late-stage-clinical-development-plans-for-proposed-biosimilar-aflibercept/2479166/Sandoz, a division of Novartis, announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT, a clinical phase 3 confirmatory efficacy and safety study, shortly.1 Aflibercept (
- Lineage Cell: OpRegen Clinical Data Continues to Demonstrate Improvements in Patients With Dry AMD With GAhttps://modernod.com/news/lineage-cell-opregen-clinical-data-continues-to-demonstrate-improvements-in-patients-with-dry-amd-with-ga/2479160/Lineage Cell Therapeutics announced that updated interim results from its ongoing, 24-patient phase 1/2a clinical study of its lead product candidate, OpRegen, were reported at the 2021 Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2021). OpRegen is an investigational